Replimune Stock: Modeling The Coin Flip Of FDA Approval (NASDAQ:REPL)
· seekingalpha.com
Replimune (REPL) faces a binary FDA decision on RP1 in advanced melanoma. RP1 approval could push REPL to $14.99/share. See more here.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...